split-banner-image

TIBER

Closed

ANZ 0201/1839IL/0067: TIBER

A multicentre open-label, non-comparative, two-arm, phase II trial of ZD1839 (IRESSA) in patients with hormone-insensitive (ER and PgR-negative) or hormone-resistant (ER and/or PgR-positive) metastatic or inoperable locally advanced breast cancer.

international

0

INTERNATIONAL

Total number of trial

participants internationally

australia & new zealand

66

AUSTRALIA & NEW ZEALAND

Total number of trial participants

in Australia and New Zealand

institutions

16

INSTITUTIONS

Total number of participating institutions

in Australia and New Zealand

TIBER PUBLICATIONS

2009

Gefitinib treatment in hormone-resistant and hormone receptor-negative advanced breast cancer.

Green MD, Francis PA, Gebski V, Harvey V, Karapetis C, Chan A, Snyder R, Fong A, Basser R, Forbes JF, on behalf of the Australian New Zealand Breast Cancer Trials Group. Ann Oncol 2009; 20(11):1813-1817, Journal

2006

Australian New Zealand Breast Cancer Trials Group: Translational research protocols.

Forbes JF. HMRI Conference on Translational Research 2006; Poster P-07, Poster

2005

Gefitinib has a low clinical benefit rate in advanced breast cancer patients.

Francis P, Green M, Gebski V, Harvey V, Karapetis C, Chan A, Snyder R, Forbes JF. San Antonio Breast Cancer Symp 2005; Poster 4080, Poster

Institutions